
Xenetic Biosciences XBIO
€ 2.42
-0.54%
Geschäftsbericht 2025
hinzugefügt 12.03.2026
Land |
|
IPO-Jahr |
- |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ CAPITAL |
Anteile |
1.7 M |
Marktkapitalisierung |
$ 4.75 M |
EBITDA (LTM) |
$ -6.53 M |
P/E (LTM) |
-1.7 |
P/S (LTM) |
1.69 |
EPS (LTM) |
-1.65 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Veracyte
VCYT
|
$ 31.01 | -5.46 % | $ 2.44 B | Nasdaq Global Market,SPB | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Vir Biotechnology
VIR
|
$ 8.47 | -5.47 % | $ 1.17 B | Nasdaq Global Select Market,SPB | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Viking Therapeutics
VKTX
|
$ 32.67 | -4.61 % | $ 3.68 B | Nasdaq Capital Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Viridian Therapeutics
VRDN
|
$ 27.39 | -2.87 % | $ 2.79 B | Nasdaq Capital Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 437.99 | -3.47 % | $ 112 B | Nasdaq Global Select Market,SPB | ||
|
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Verastem
VSTM
|
$ 5.01 | -5.29 % | $ 347 M | Nasdaq Global Market | ||
|
VistaGen Therapeutics
VTGN
|
$ 0.56 | -7.23 % | $ 17.3 M | Nasdaq Global Select Market | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 12.88 | -7.74 % | $ 1.95 B | Nasdaq Global Select Market,SPB | ||
|
vTv Therapeutics
VTVT
|
$ 38.69 | 2.35 % | $ 152 M | Nasdaq Global Select Market | ||
|
Voyager Therapeutics
VYGR
|
$ 3.97 | -4.0 % | $ 233 M | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 320.49 | -2.34 % | $ 42 B | Nasdaq Global Select Market,SPB | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | ||
|
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.07 | -1.82 % | $ 21.9 M | Nasdaq Capital Market | ||
|
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Equillium
EQ
|
$ 1.93 | -6.31 % | $ 111 M | Nasdaq Global Market | ||
|
Amgen
AMGN
|
$ 351.01 | -0.61 % | $ 189 B | Nasdaq Global Select Market,SPB |